Gary Veron Joins Hogan Lovells’ Government Regulatory Practice in Washington, D.C.
19 February 2013
WASHINGTON, D.C., 19 February 2013 – Hogan Lovells announced today that Gary Veron has joined its Government Regulatory practice as a partner in the Washington, D.C. office. Veron joins from Sidley Austin LLP where he served as counsel in the food and drug practice.
Veron focuses his practice on food and drug law with an emphasis on the intersection of regulatory law and intellectual property law for pharmaceutical and biotechnology products. He represents pharmaceutical, biotechnology and medical device companies on a wide range of U.S. Food and Drug Administration (FDA) regulatory and enforcement matters.
Veron's practice over the last 10 years has focused primarily on the Hatch-Waxman Act and life-cycle management issues. He is a frequent advocate before the FDA on behalf of manufacturers of pioneer and brand name pharmaceuticals. In a recent complex petition matter, Veron won a significant ruling limiting the ability of generic drug applicants to avoid a pioneer company's exclusivity rights.
“Pharmaceutical and biotechnology companies face unprecedented pressures in terms of product development, approval, and competition in the marketplace,” said Philip Katz, Practice Area Leader of Hogan Lovells’ pharmaceutical and biotechnology practice group. “Gary’s experience with Hatch-Waxman and biosimilars issues, coupled with his understanding of the industry, allow him to creatively and effectively advise and represent clients. He is a highly valued and significant addition to our practice.”
Veron is a registered patent attorney and before practicing law served as a technology development specialist in the U.S. National Institutes of Health (NIH), and as legislative counsel to the Maryland General Assembly.
“Hogan Lovells has one of the largest and most sophisticated pharma and biotech life cycle management practices,” said Veron. “I’m excited about joining a team with a demonstrated record of success in bringing intellectual property and regulatory law together on behalf of the leading pharmaceutical and biotechnology companies.”
Veron holds a J.D. from the University of Virginia School of Law and a B.S. in biology from Virginia Polytechnic Institute.